Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?

Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$353.86M+5.7%	-$390.98M-5.1%	-$397.63M+3.0%	-$389.92M+11.4%	-$375.36M+16.5%
Depreciation and amortization	$12.93M+9.2%	$12.68M+3.5%	$12.23M+2.5%	$12.25M+3.5%	$11.85M+1.0%
Stock-based compensation	$49.93M-56.7%	$61.58M-43.8%	$80.74M-13.2%	$99.84M+28.2%	$115.36M+79.9%
Deferred income taxes	-$1.08M—	-$2.26M—	——	——	——
Gain (loss) on sale of assets	——	——	——	——	-$7.4M—
Change in accounts receivable	$10.82M-84.7%	$13.11M-81.1%	$10.99M-80.3%	$28.33M-10.2%	$70.7M+30,376%
Change in inventories	——	——	——	——	$51.48M+199%
Change in accounts payable	$7.18M—	-$6.66M—	-$7.52M—	——	——
Change in accrued liabilities	$5.63M-83.4%	$28.92M+237%	$11.83M-14.9%	$19.04M+11.1%	$33.84M+482%
Change in other assets	——	——	——	——	——
Amortization of intangible assets	$23.42M-14.0%	$23.2M-12.0%	$27.72M+41.8%	$27.42M+52.0%	$27.22M+88.5%
Net gains (losses) on investments	——	——	——	——	——
Non-cash operating lease expense	$10.39M-5.6%	$11.39M+9.1%	$11.84M+16.9%	$11.5M+9.6%	$11.01M-0.6%
Change in operating lease liabilities	-$9.81M+20.8%	-$10.9M+9.7%	-$11.65M-4.6%	-$12.19M-10.7%	-$12.4M-12.6%
Net cash from operating activities	-$270.79M+19.0%	-$302.41M+14.3%	-$323.14M+11.1%	-$303.41M+22.0%	-$334.39M+13.0%
Capital expenditures	$34.23M+161%	$33.84M+206%	$28.68M+175%	$20.13M+71.8%	$13.11M-37.0%
Purchases of investments	$276.74M-33.6%	$318.67M-30.8%	$346.92M-27.8%	$411.29M-1.3%	$416.93M+21.8%
Proceeds from maturities/sales of investments	$354M-23.2%	$400M-6.5%	$446M+27.4%	$436M+67.1%	$461M+121%
Net cash from investing activities	$43.02M—	$47.5M—	——	——	——
Proceeds from issuance of common stock	$255.88M-26.5%	$306.31M-22.9%	$250.53M-36.9%	$209.53M-62.1%	$348.34M-13.2%
Taxes paid for net share settlement	$5.59M-59.5%	$7.06M-45.1%	$7.49M-38.4%	$13.31M+112%	$13.8M+148%
Net cash from financing activities	$251.79M-26.0%	$300.77M-23.0%	$246.91M-36.6%	$200.81M-63.5%	$340.4M-14.5%
Effect of exchange rate changes on cash	——	——	——	$1.32M—	$458K—
Net increase (decrease) in cash	——	——	——	——	$37.43M+109%
Accretion (Amortization) of Discounts and Premiums, Investments	$6.18M-38.7%	$7.2M-29.8%	$8.63M-6.3%	$9.58M+26.3%	$10.07M+98.1%
Amortization of capitalized software and acquired intangible assets	$23.42M-14.0%	$23.2M-12.0%	$27.72M+41.8%	$27.42M+52.0%	$27.22M+88.5%
Foreign currency remeasurement (loss) gain on debt	-$137K—	$238K—	——	——	——
Gain (Loss) on Disposition of Assets	——	——	——	——	——
Gain on termination of lease	——	——	——	——	——
Operating lease liabilities	-$9.81M+20.8%	-$10.9M+9.7%	-$11.65M-4.6%	-$12.19M-10.7%	-$12.4M-12.6%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Inventory write-downs	$12.9M—	$13.4M—	——	——	——
Operating lease right-of-use asset amortization	$10.39M-5.6%	$11.39M+9.1%	$11.84M+16.9%	$11.5M+9.6%	$11.01M-0.6%
Proceeds From Sale And Maturity Of Available For Sale Securities	$354M-23.2%	$400M-6.5%	$446M+27.4%	$436M+67.1%	$461M+121%
Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense	——	——	——	-$18.31M—	-$13.17M—
Exchange Offer (Note 12)	——	——	——	——	——
Increase Decrease In Operating Lease Liability	-$9.81M+20.8%	-$10.9M+9.7%	-$11.65M-4.6%	-$12.19M-10.7%	-$12.4M-12.6%
Right Of Use Asset Obtained Reduced In Exchange For Operating Lease Liability From Lease Modifications	——	——	——	——	——
Unrealized Gain (Loss) on Investments	——	——	——	——	——
Free cash flow	-$305.02M+12.2%	-$336.24M+7.6%	-$351.82M+6.0%	-$323.54M+19.2%	-$347.5M+14.2%
Free cash flow	-$305.02M+12.2%	-$336.24M+7.6%	-$351.82M+6.0%	-$323.54M+19.2%	-$347.5M+14.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?: Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.